Hey everybody, today I talk about the upcoming advisory committee meeting, which will lead to a recommendation (or not) for the approval of Descovy for pre-exposure prophylaxis (PrEP) in high-risk individuals. I also go through the latest ICER reports on AIMT and AMRN.
I mention a short-term trade idea but remember to do your own due diligence and do not consider this investment advice.
On this episode, I talk about results from the Gilead Phase 3 NASH trial that announced no improvement in patients treated with Selonsertib (ASK1 inhibitor). I also talk about the DBVT BLA resubmission and a hot hot Q319 trading idea on CBIO.
Relevant links:
https://www.gilead.com/news-and-press/press-room/press-releases
https://www.dbv-technologies.com/investor-relations/press-releases/
http://ir.catalystbiosciences.com/news-releases
*this is not investment advice, only my opinion and ideas*
http://www.breakingbiotech.com
#biotech #breakingbiotech #nash
-Gilead loses 3 executives in the last 6 months, but that’s not why I sold!
-New research suggests that closed-loop insulin delivery-glucose monitoring keeps type 2 diabetics in range better than conventional therapy
*this is not investment advice*
